TG Therapeutics (TGTX) Reports Data From Phase 2 Clinical Trial of TG-1101 with Ibrutinib at ASH
Tweet Send to a Friend
TG Therapeutics, Inc. (Nasdaq: TGTX), today announced clinical results from its Phase 2 study of TG-1101 (ublituximab), the Company's novel ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
